Clinic
Providence Hospital, LLC
Providence Hospital, LLC was paid $12.68M by Medicaid between Jan 2018 and Aug 2021, across 194 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoPROVIDENCE HOSPITAL, LLC
COLUMBIA, SC 29204
COLUMBIA, SC 29204
33aNPI1003811290assigned 06/15/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$12.68M
24GClaims363,905
24DCodes billed194
24AFirst – last monthJan 2018 – Aug 2021
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in South Carolina
Rank by total paid#1 of 38
Median peer was paid$106K
This provider vs. median120×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TEAGUE, KATHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,451 | $3.77M | |
| 2019 | 118,334 | $4.18M | |
| 2020 | 87,375 | $2.88M | |
| 2021 | 53,745 | $1.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 16,522 | 14,003 | $1.99M |
| 36415 | Collection of venous blood by venipuncture | 9.5% | 9,122 | 6,015 | $1.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 18,326 | 16,391 | $1.08M |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.4% | 9,750 | 7,724 | $808K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.0% | 3,547 | 3,023 | $640K |
| 81003 | 4.8% | 18,551 | 16,460 | $607K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 6,460 | 5,709 | $607K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.0% | 18,536 | 16,614 | $508K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.7% | 2,391 | 2,202 | $465K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 5,848 | 4,951 | $261K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 1,032 | 932 | $240K |
| 87430 | 1.9% | 2,811 | 2,616 | $236K |
182 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,594 | $226K |
| 84702 | 1.7% | 1,466 | $211K | |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 5,066 | $206K |
| 87210 | 1.5% | 1,970 | $193K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 608 | $174K |
| 87899 | 1.4% | 769 | $172K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 383 | $171K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 3,237 | $145K |
| 81025 | 1.1% | 11,511 | $140K | |
| 73130 | 1.1% | 849 | $137K | |
| 71045 | Radiologic examination, chest; single view | 1.0% | 8,132 | $129K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,840 | $125K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,162 | $120K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,389 | $113K |
| 73030 | <1% | 1,068 | $111K | |
| 73630 | <1% | 1,167 | $111K | |
| 73610 | <1% | 736 | $108K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,326 | $108K |
| 73560 | <1% | 1,160 | $93K | |
| 99285 | Emergency room visit (most serious) | <1% | 14,669 | $71K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 509 | $69K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,473 | $68K |
| 72100 | <1% | 1,245 | $64K | |
| 72040 | <1% | 456 | $55K | |
| 73110 | <1% | 410 | $55K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 602 | $54K |
| 87077 | <1% | 787 | $45K | |
| 93458 | <1% | 630 | $44K | |
| 10060 | <1% | 305 | $40K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,719 | $36K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,740 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,294 | $32K |
| 93017 | <1% | 744 | $31K | |
| 76377 | <1% | 543 | $30K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 686 | $28K |
| 82962 | <1% | 343 | $23K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,604 | $23K |
| 93970 | <1% | 209 | $20K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 500 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,919 | $20K |
| 72050 | <1% | 195 | $18K | |
| 93971 | <1% | 596 | $18K | |
| 73070 | <1% | 109 | $18K | |
| 73502 | <1% | 335 | $18K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,665 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,870 | $17K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 374 | $16K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 300 | $15K |
| 29581 | <1% | 312 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 431 | $13K |
| 12001 | <1% | 71 | $12K | |
| 73562 | <1% | 101 | $11K | |
| 86900 | <1% | 1,211 | $11K | |
| 74019 | <1% | 357 | $11K | |
| C1769 | Guide wire | <1% | 1,210 | $9K |
| 96376 | <1% | 1,075 | $8K | |
| 88304 | <1% | 94 | $7K | |
| 73140 | <1% | 27 | $7K | |
| 84703 | <1% | 960 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 1,730 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 643 | $7K |
| 74018 | <1% | 220 | $6K | |
| 73090 | <1% | 34 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 31 | $6K |
| 12011 | <1% | 27 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,558 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 64 | $5K |
| 70486 | <1% | 128 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 85 | $5K |
| 84484 | <1% | 7,748 | $5K | |
| 0001A | <1% | 127 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 55 | $4K |
| 85379 | <1% | 2,664 | $4K | |
| 73590 | <1% | 67 | $4K | |
| 85027 | <1% | 3,646 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 162 | $4K |
| 91300 | <1% | 167 | $3K | |
| 81001 | <1% | 173 | $3K | |
| 72072 | <1% | 79 | $3K | |
| 83690 | <1% | 5,680 | $3K | |
| A9270 | Non-covered item or service | <1% | 12,790 | $3K |
| 93880 | <1% | 15 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 522 | $2K |
| 71250 | <1% | 68 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,688 | $2K |
| 80061 | Lipid panel | <1% | 1,427 | $2K |
| 93922 | <1% | 12 | $2K | |
| 87420 | <1% | 179 | $2K | |
| 94644 | <1% | 526 | $2K | |
| 12002 | <1% | 18 | $2K | |
| 85610 | <1% | 2,665 | $1K | |
| 83735 | <1% | 5,214 | $1K | |
| 85730 | <1% | 1,539 | $1K | |
| 83880 | <1% | 2,051 | $974.51 | |
| 87070 | <1% | 45 | $967.64 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,852 | $950.97 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,398 | $873.04 |
| 87081 | <1% | 2,409 | $856.12 | |
| 76801 | <1% | 119 | $831.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,668 | $764.55 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,218 | $644.91 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 486 | $629.55 |
| 82803 | <1% | 103 | $533.66 | |
| 84439 | <1% | 140 | $489.90 | |
| 76830 | Ultrasound, transvaginal | <1% | 40 | $488.88 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,457 | $485.67 |
| 87631 | <1% | 33 | $436.06 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,059 | $432.49 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 322 | $419.83 |
| 83605 | <1% | 1,037 | $317.98 | |
| 80076 | <1% | 412 | $291.11 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,192 | $223.78 |
| 82550 | <1% | 787 | $221.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,145 | $141.29 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 651 | $128.32 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,865 | $124.85 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 734 | $120.00 |
| 82272 | <1% | 34 | $116.18 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,519 | $104.31 |
| 0002A | <1% | 124 | $97.13 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,848 | $87.78 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 991 | $77.96 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 199 | $75.00 |
| 97162 | <1% | 16 | $72.81 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,605 | $48.73 |
| 80074 | <1% | 32 | $44.05 | |
| 82043 | <1% | 14 | $28.18 | |
| 87040 | <1% | 644 | $23.22 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 112 | $21.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,031 | $21.67 |
| 86901 | <1% | 1,212 | $13.68 | |
| 82570 | <1% | 117 | $11.33 | |
| 87186 | <1% | 803 | $11.24 | |
| 82607 | <1% | 49 | $6.60 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 327 | $4.59 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,072 | $1.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,857 | $0.23 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,798 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 289 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,615 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,094 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 123 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 98 | $0.00 |
| 85651 | 0% | 50 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 223 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 219 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 100 | $0.00 |
| 88342 | 0% | 45 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 632 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 56 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 29 | $0.00 |
| 82150 | 0% | 29 | $0.00 | |
| 86141 | 0% | 30 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 143 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| 87205 | 0% | 46 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 114 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 17 | $0.00 |
| 82746 | 0% | 25 | $0.00 | |
| 82728 | 0% | 29 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 216 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 63 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,382 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,090 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 244 | $0.00 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 0% | 40 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 710 | $0.00 |
| 85045 | 0% | 22 | $0.00 | |
| 84100 | 0% | 201 | $0.00 | |
| 90715 | 0% | 86 | $0.00 | |
| 84156 | 0% | 13 | $0.00 | |
| 85347 | 0% | 62 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 82 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 59 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 44 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 78 | $0.00 |
| 86038 | 0% | 13 | $0.00 | |
| 36600 | 0% | 13 | $0.00 | |
| 84550 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 43 | $0.00 |
| 83540 | 0% | 12 | $0.00 | |
| 83970 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTEAGUE, KATHY (ASSISTANT VICE PRESIDENT, SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Rchp-Wilmington, LLC | Wilmington, OH | $13.53M |
| Vaughan Regional Medical Center LLC | Selma, AL | $8.15M |
| Kershaw Hospital LLC | Camden, SC | $7.93M |
| Bolivar Physician Practices LLC | Cleveland, MS | $3.05M |
| Wilmington Physicians Group LLC | Wilmington, OH | $3.04M |
| Phc-Morgan City LP | Morgan City, LA | $2.37M |
| Community Hospital of Andalusia LLC | Andalusia, AL | $2.27M |
| Vaughan Regional Medical Center LLC | Marion, AL | $2.15M |
| PRHC Ennis LP | Ennis, TX | $1.81M |
| Andalusia Physician Practices LLC | Andalusia, AL | $847K |
| Meadowview Physician Practice LLC | Maysville, KY | $783K |
| Logan Physician Practice LLC | Auburn, KY | $458K |
| Logan Physician Practice LLC | Russellville, KY | $317K |
| Kentucky Mso LLC | Georgetown, KY | $248K |
| Rchp-Wilmington, LLC | Wilmington, OH | $165K |
| Meadowview Physician Practice LLC | Maysville, KY | $140K |
| Amg-Southern Tennessee LLC | Monteagle, TN | $136K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $135K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $57K |
| Kershaw Hospital LLC | Lugoff, SC | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.